INT196812

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 0.13
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (Ppp1r1b, Ppp1cc) nucleus (Ppp1r1b, Ppp1cc) mitochondrion (Ppp1cc)
intracellular (Ppp1r1b) carbohydrate metabolic process (Ppp1cc) protein complex (Ppp1cc)
Ppp1r1b (Mus musculus)
Ppp1cc (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 125 98.12 Very High Very High Very High
sSRI 91 95.72 Very High Very High Very High
fluoxetine 2 92.72 High High
Neurotransmitter 13 84.56 Quite High
Glutamate 31 82.24 Quite High
adenocard 2 80.72 Quite High
Opioid 1 78.88 Quite High
Nucleus accumbens 1 73.24 Quite High
antidepressant 39 69.60 Quite High
long-term potentiation 23 64.96 Quite High
Disease Link Frequency Relevance Heat
Leukemia 1 78.20 Quite High
Depression 67 56.08 Quite High
Manic Depressive Disorder 3 38.88 Quite Low
Congenital Anomalies 6 7.80 Low Low
Affective Disorder 12 5.00 Very Low Very Low Very Low
Adhesions 6 5.00 Very Low Very Low Very Low
Stress 6 5.00 Very Low Very Low Very Low
Suicidal Behaviour 5 5.00 Very Low Very Low Very Low
Neurodegenerative Disease 4 5.00 Very Low Very Low Very Low
Anxiety Disorder 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As DARPP-32 phosphorylated by PKA inhibits protein phosphatase 1 (PP-1), reduction of PKA activity by GABABR would release PP-1 from the inhibition.
DARPP-32 Negative_regulation (inhibits) of PP-1
1) Confidence 0.07 Published 2009 Journal Mol Syst Biol Section Body Doc Link PMC2710870 Disease Relevance 0 Pain Relevance 0.11
It produces a positive-feedback loop in the molecular network, because PDE1 inhibition increases the intracellular cAMP concentration, thus promoting the PKA activity, which in turn supports the CaMKII activity through inhibition of PP-1 by phospho-DARPP-32.
phospho-DARPP-32 Negative_regulation (inhibition) of PP-1
2) Confidence 0.07 Published 2009 Journal Mol Syst Biol Section Body Doc Link PMC2710870 Disease Relevance 0 Pain Relevance 0.09
The increase in cAMP concentration caused by PDE1 inhibition would lead to the increased PKA activity, which would in turn support the CaMKII activity through facilitating the inhibition of PP-1 by phospho-DARPP-32.
phospho-DARPP-32 Negative_regulation (inhibition) of PP-1
3) Confidence 0.07 Published 2009 Journal Mol Syst Biol Section Body Doc Link PMC2710870 Disease Relevance 0 Pain Relevance 0
When phosphorylated at Thr34, DARPP-32 is a potent inhibitor of PP1 [14], whereas when phosphorylated at Thr75 DARPP-32 inhibits protein kinase A (PKA) [15].
DARPP-32 Negative_regulation (inhibitor) of PP1
4) Confidence 0.07 Published 2006 Journal PLoS Computational Biology Section Body Doc Link PMC1562452 Disease Relevance 0 Pain Relevance 0.39
DARPP-32 is an inhibitor of protein phosphatase-1 (PP1).
DARPP-32 Negative_regulation (inhibitor) of PP1
5) Confidence 0.03 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2426818 Disease Relevance 0.13 Pain Relevance 0.53

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox